A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia

被引：0
作者：
Ghobrial, Irene M.
Gertz, Morie A.
LaPlant, Betsy
Camoriano, John [3 ]
Hayman, Suzanne R.
Lacy, Martha Q.
Chuma, Stacey
Sheehy, Patricia [1 ]
Harris, Brianna
Leduc, Renee
Rourke, Meghan
Ansell, Stephen M. [2 ]
DeAngelo, Daniel J. [1 ]
Dispenzieri, Angela
Bergsagel, Leif [3 ]
Reeder, Craig B. [3 ]
Anderson, Kenneth C.
Richardson, Paul
Treon, Steven
Witzig, Thomas E. [2 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Mayo Clin, Coll Med, Rochester, MN USA
[3] Mayo Clin, Scottsdale, AZ USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：244 / 244
页数：1
相关论文
共 50 条
  • [31] A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)
    Slomovitz, B. M.
    Lu, K. H.
    Johnston, T.
    Munsell, M.
    Ramondetta, L. M.
    Broaddus, R. R.
    Coleman, R. L.
    Walker, C.
    Gershenson, D. M.
    Burke, T. W.
    Wolf, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma.
    Rao, R. D.
    Windschitl, H. E.
    Allred, J. B.
    Lowe, V. J.
    Maples, W. J.
    Gornet, M. K.
    Suman, V. J.
    Creagan, E. T.
    Pitot, H. C.
    Markovic, S. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 463S - 463S
  • [33] A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.
    Mayer, I. A.
    Means-Powell, J.
    Shyr, Y.
    Arteaga, C. L.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 677S - 677S
  • [34] Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    [J]. BLOOD, 2009, 114 (22) : 1481 - 1481
  • [35] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced Hematologic malignancies
    Yee, K
    O'Brien, S
    Wierda, W
    Thomas, D
    Kurzrock, R
    Fayad, L
    Hagemeister, F
    Goy, A
    Cortes, J
    Prestifilippo, J
    Szatrowski, T
    Kantarjian, H
    Giles, F
    [J]. JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : S35 - S35
  • [36] Perifosine: Final Results of a Phase II Trial in Relapsed/Refractory Waldenstrom Macroglobulinemia
    Ghobrial, I. M.
    Roccaro, A. M.
    Sportelli, P.
    Treon, S. P.
    Weller, E.
    Leleu, X.
    Rubin, N.
    Hong, F.
    Leduc, R.
    Chuma, S.
    Nelson, M.
    C'Connor, K.
    Sam, A.
    Harris, B.
    Warren, D.
    Anderson, K. C.
    Richardson, P. G.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S83 - S83
  • [37] Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia
    Ghobrial, I. M.
    Matous, J.
    Padmanabhan, S.
    Badros, A.
    Chuma, S.
    Leduc, R.
    Rourke, M.
    Kunsman, J.
    Harris, B.
    Warren, D.
    Richardson, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Matous, Jeffrey
    Padmanabhan, Swaminathan
    Badros, Ashraf
    Schlossman, Robert
    Chuma, Stacey
    Leduc, Renee
    Nelson, Marybeth
    O'Connor, Kelly
    Sam, Amy
    Harris, Brianna
    Soumerai, Jacob
    Warren, Diane
    Birner, Ann
    Munshi, Nikhil
    Treon, Steven P.
    Anderson, Kenneth C.
    Richardson, Paul
    [J]. BLOOD, 2008, 112 (11) : 308 - 309
  • [39] SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
    Ou, Sai-Hong Ignatius
    Moon, James
    Garland, Linda L.
    Mack, Philip C.
    Testa, Joseph R.
    Tsao, Anne S.
    Wozniak, Antoniette J.
    Gandara, David R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 387 - 391
  • [40] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Kensei Tobinai
    Michinori Ogura
    Dai Maruyama
    Toshiki Uchida
    Naokuni Uike
    Ilseung Choi
    Kenichi Ishizawa
    Kuniaki Itoh
    Kiyoshi Ando
    Masafumi Taniwaki
    Naomi Shimada
    Ken Kobayashi
    [J]. International Journal of Hematology, 2010, 92 : 563 - 570
12345